Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major ...

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Florida ,New York ,Texas ,Tampa ,Rakesh Jain ,Roger Mcintyre ,Darren Opland ,Greg Mattingly ,Mark Jacobson ,Nasdaq ,Us Department Of Health ,Human Services ,Corporate Communications ,Texas Tech University School Of Medicine ,World Trade Center ,American College Of Neuropsychopharmacology ,Axsome Therapeutics Inc ,Clinical Professor Of Psychiatry At Washington University ,Mental Health Indicators ,World Health Organization ,National Survey On Drug ,Midwest Research Group ,University Of Toronto ,Drug Administration ,Department Of Psychiatry ,National Institutes Of Health ,American College ,Major Depressive Disorder Using ,Depressive Symptoms ,Patients With One Prior Treatment Failure ,Evolve Long Term ,Associate Clinical Professor ,Washington University ,Midwest Research ,Withdrawal Symptoms After Discontinuation ,Results From ,Clinical Professor ,Texas Tech University School ,National Institutes ,Breakthrough Therapy ,Prescribing Information ,Boxed Warning ,Axsome Therapeutics ,Key Substance Use ,Drug Use ,Published October ,Dis Treat ,Region ,